Investor Alert

Market Pulse Archives

June 15, 2021, 9:36 a.m. EDT

Novavax says efficacy of COVID-19 vaccine isn't affected when co-administered with the flu shot

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Novavax Inc. /zigman2/quotes/202614340/composite NVAX +0.11% were down 0.9% in trading on Tuesday, the day after the company said a study evaluating co-vaccination against COVID-19 and the flu demonstrated similar efficacy to administering Novavax's experimental COVID-19 shot alone. "Separate health care visits to cover both COVID-19 and influenza vaccinations will be burdensome," a Novavax executive said in a news release. As part of the Phase 3 clinical trial for its coronavirus vaccine in the U.K., the company also enrolled 431 participants in a sub-study that gave participants both the COVID-19 vaccine and the flu shot. In the preprint , published Sunday, the researchers found that the immunogenicity of the flu shot was the same, while there was a "modest decrease" in the immunogenicity of the COVID-19 shot. Novavax also announced this week that its coronavirus vaccine had an efficacy rate of 90.4% when it comes to preventing symptomatic infection in roughly 30,000 participants enrolled in the Phase 3 clinical trial in the U.S. Novavax's stock has soared 86.2% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.91% is up 13.3%.

US : U.S.: Nasdaq
$ 237.54
+0.27 +0.11%
Volume: 3.14M
Sept. 17, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$17.69 billion
Rev. per Employee
-40.76 -0.91%
Volume: 3.79B
Sept. 17, 2021 5:25p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.